Clinical subgroups in bilateral Meniere disease

Frontiers in Neurology

Pedro Marques¹  Gabriel Trinidad²  Andres Soto-Varela³  Sofia Santos³  Ismael Aran⁴  Jesus Fraile⁵  Jesus Benitez⁶  Herminio Perez-Garrigues⁷  Vanesa Perez-Guillen⁷  Rocio Gonzalez-Aguado⁸  Angel Batuecas-Caletrio⁹  Ana Garcia-Arumi^1,10  Eduardo Martin-Sanz^1,11  Paz Perez^1,12  Maria Cruz Tapia^1,13  Juan M. Espinosa-Sanchez^1,14  Jose Antonio Lopez-Escamez^1,14  Lidia Frejo^1,14 

[1] Centro Hospitalar de S.João, EPE, University of Porto Medical School;Complejo Hospitalario de Badajoz;Complexo Hospitalario Universitario Santiago de Compostela;Complexo Hospitalario de Pontevedra;Hospital Miguel Servet;Hospital Universitario Gran Canaria Dr. Negrin;Hospital Universitario La Fe;Hospital Universitario Marques de Valdecilla;Hospital Universitario Salamanca;Hospital Universitario Vall d'Hebron;Hospital Universitario de Getafe;Hospital de Cabueñes;Instituto Antoli-Candela;Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitalario Universidad de Granada;

关键词: Hearing Loss;    Tinnitus;    Migraine;    Cluster analysis;    Inner ear;    vestibular disorders;   

DOI  :  10.3389/fneur.2016.00182

来源: DOAJ

【 摘 要 】

Meniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms and tinnitus associated with several comorbidities such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5-50% and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of bilateral MD and to develop new treatments. We have defined five clinical variants in bilateral MD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to bilateral MD.

【 授权许可】

Unknown